Results 151 to 160 of about 18,936 (261)

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

open access: yesAdvanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong   +8 more
wiley   +1 more source

FDA-approved candidate drug selection.

open access: yes
AUC; area under the curve of AE-NN. (A) Candidate drugs for the RD cell line. (B) Candidate drugs for the SJCRH30 cell line.
Eunmi Jang (17854725)   +6 more
core   +1 more source

FUCA2 Sustains AKT Signaling and Suppresses Senescence by Antagonizing FUT3‐Mediated ErbB3 Fucosylation in Lung Adenocarcinoma

open access: yesAdvanced Science, EarlyView.
ABSTRACT While targeted therapies have improved outcomes in lung adenocarcinoma (LUAD), many patients still lack targetable mutations. Here, we identified alpha‐L‐fucosidase 2 (FUCA2) as a crucial driver of LUAD by preventing cellular senescence. Mechanistically, through the restriction of fucosyltransferase 3 (FUT3)‐mediated α‐1,3‐fucosylation of ...
Lu Chen   +18 more
wiley   +1 more source

Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry [PDF]

open access: yes
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S.
Daron Acemoglu, Joshua Linn
core  

Divergent Roles of mGlu2 and mGlu3 Receptors in Amyloid‐β Production and Cognitive Dysfunctions in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
This study explores the opposing effects of the mGluR2 and mGluR3 receptors on amyloid precursor protein processing. mGluR2 promotes amyloidogenic cleavage, while mGluR3 favors non‐amyloidogenic pathways. Using a brain‐penetrant nanobody as a mGluR2 positive allosteric modulator, the study uncovers how its chronic activation aggravates amyloid‐β burden
Pierre‐André Lafon   +21 more
wiley   +1 more source

Uncertainty in the Generic Versus Brand Name Prescription Decision

open access: yes
This paper analyzes the impact of uncertainty concerning product quality of generic drugs on the substitution behavior of prescribing physicians. It is shown that uncertainty about the generic drug quality gives the physician a value of waiting for more ...
Hellström, Jörgen, Rudholm, Niklas
core  

Epigenetic Silencing of RFX7 Defines a Transcriptional Axis Linking Lactate Metabolism to Immune Checkpoint Therapy in Glioblastoma

open access: yesAdvanced Science, EarlyView.
Glioblastoma (GBM) exhibits RFX7 silencing via promoter hypermethylation, which downregulates PIK3IP1 to activate PI3K/AKT signaling, increase lactate accumulation, and enhance histone H4K12 lactylation. This lactylation upregulates PD‐L1/CSF1 expression and drives the immunosuppressive microenvironment formation.
Liying Han   +20 more
wiley   +1 more source

FDA New Drug Approval Times, Prescription Drug User Fees, and R & D Spending

open access: yes
FDA-approval times have declined significantly since the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992. As a result, present value expected returns to pharmaceutical R&D have likely increased.
Golec, Joseph H.   +3 more
core  

An Implantable Optogenetics‐Engineered Hydrogel for Amelioration of Rheumatoid Arthritis through Light‐Controlled Metabolic Reprogramming of Synovial Macrophages

open access: yesAdvanced Science, EarlyView.
An implantable hydrogel is designed to enable in situ and on‐demand secretion of GLP‐1 in synovium through blue light irradiation to activate GLP‐1R/HK2/VDAC1 pathway for upregulating tricarboxylic acid cycle and oxidative phosphorylation in macrophage, facilitating tissue repair and bone erosion recovery.
Dahai Hu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy